| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Enzon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.06 |
| 52 Week High | US$0.18 |
| 52 Week Low | US$0.046 |
| Beta | 0.48 |
| 11 Month Change | -31.25% |
| 3 Month Change | -45.98% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| EZ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.9% | -0.4% | -1.8% |
| 1Y | n/a | -15.4% | 13.6% |
Return vs Industry: Insufficient data to determine how EZ1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how EZ1 performed against the German Market.
Price Volatility
| EZ1 volatility | |
|---|---|
| EZ1 Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EZ1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EZ1's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Rick Feinstein | enzon.com |
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.
Enzon Pharmaceuticals, Inc. Fundamentals Summary
| EZ1 fundamental statistics | |
|---|---|
| Market cap | €5.65m |
| Earnings (TTM) | €289.76k |
| Revenue (TTM) | €23.99k |
19.5x
P/E Ratio235.5x
P/S RatioIs EZ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EZ1 income statement (TTM) | |
|---|---|
| Revenue | US$26.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$26.00k |
| Other Expenses | -US$288.00k |
| Earnings | US$314.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0042 |
| Gross Margin | 100.00% |
| Net Profit Margin | 1,207.69% |
| Debt/Equity Ratio | 0% |
How did EZ1 perform over the long term?
See historical performance and comparison